Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

NRF2 deficit prevents pathologic Tau seeding and spreading in an induced tauopathy mouse model

  • López-Sampere, Yaiza
  • Mengod Soler, Pol
  • Roca-Pereira, Sergio
  • Vinyals, Antonia
  • Mato-Blanco, Xoel
  • Vela-Martínez, Marta
  • Dakterzada, Farida
  • Romero, Leila
  • Santamaría Martínez, Enrique
  • Fernández Irigoyen, Joaquín
  • Ferrer, Isidro
  • Povedano, Mónica
  • Río, José Antonio del
  • Santpere, Gabriel
  • Portero-Otín, Manuel
  • Piñol-Ripoll, Gerard
  • Andrés Benito, Pol
Background. Nuclear factor erythroid 2–related factor 2 (NRF2) regulates antioxidant defenses and protects against neurodegeneration, including Alzheimer's disease (AD). Its age-related decline disrupts redox balance and increases neuronal vulnerability, but the early hippocampal effects remain unclear. Here, we tested whether NRF2 loss affects tau seeding and spreading in a PHF-tau–inoculated mouse model, contributing to accelerated aging. Methodology. Three-month-old NRF2-knockout (Nfe2l2−/−) and wild-type (WT) mice received hippocampal inoculations of human AD-derived PHF-tau, and tau propagation was analyzed after three months. To elucidate the molecular underpinnings of the observed changes, we performed integrative phosphoproteotranscriptomic analyses of hippocampal tissue, supported by RT-qPCR and Western blot validation. Results. PHF-tau inoculation at 3 months of age in Nfe2l2−/− mice, surprisingly, exhibited markedly reduced tau seeding and spreading compared to WT after 3 months of incubation. Molecular characterization of the Nfe2l2−/− hippocampus was carried out to unravel the molecular changes associated with impaired tau propagation. Transcriptomic profiling revealed 745 deregulated genes in Nfe2l2−/− mice, characterized by upregulation of immune and metabolic pathways but downregulation of oxidative stress and redox-related genes. RT-qPCR confirmed diminished expression of antioxidant enzymes and anti-inflammatory receptors, alongside altered astrocytic markers. Proteomic analysis identified 157 dysregulated proteins associated with mitochondrial, synaptic, and inflammatory processes, while phosphoproteomics detected 824 altered phosphosites enriched in cytoskeletal and synaptic networks. Western blot showed increased GFAP-C-term, AQP4, 8-OHdG, and MDAL, with reduced GSTM2 expression. Notably, total and 4R-tau levels were decreased, while 3R-tau was elevated in Nfe2l2−/− mice. Conclusion. Our findings suggest that NRF2 loss induces a hippocampal state marked by impaired antioxidant defenses, astrocytic remodeling, and disrupted tau isoform balance. This environment, while metabolically altered, paradoxically hinders tau propagation, highlighting NRF2 as a key regulator of both redox and cellular maturity programs essential for tau spread and as a potential therapeutic target in tauopathies., MPO was supported by grants from the Instituto de Salud Carlos III (PI20/000155, PI23/00176), and PAB was supported by grants from the same governmental institution (CD23/00097). The project that gave rise to these results received the support of a fellowship to PMS from Fundación Ramón Areces. We want to particularly acknowledge patients and Biobank HUB-ICO-IDIBELL (PT20/00171) integrated in the ISCIII Biobanks and Biomodels Platform and Xarxa Banc de Tumors de Catalunya (XBTC) for their collaboration. We thank CERCA Programme/Generalitat de Catalunya for institutional support.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

TDP-43 regulates LC3ylation in neural tissue through ATG4B cryptic splicing inhibition

  • Torres, Pascual
  • Rico-Ríos, Santiago
  • Ceron-Codorniu, Miriam
  • Santacreu-Vilaseca, Marta
  • Seoane-Miraz, David
  • Jad, Yahya
  • Ayala, Victòria
  • Mariño, Guillermo
  • Beltrán, Maria
  • Miralles, Maria P.
  • Andrés Benito, Pol
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • López-Otín, Carlos
  • Soler, Rosa M.
  • Povedano, Mónica
  • Ferrer, Isidro
  • Pamplona, Reinald
  • Wood, Matthew J. A.
  • Varela, Miguel A.
  • Portero-Otín, Manuel
Amyotrophic lateral sclerosis (ALS) is an adult-onset motor neuron disease with a mean survival time of three years. The 97% of the cases have TDP-43 nuclear depletion and cytoplasmic aggregation in motor neurons. TDP-43 prevents non-conserved cryptic exon splicing in certain genes, maintaining transcript stability, including ATG4B, which is crucial for autophagosome maturation and Microtubule-associated proteins 1A/1B light chain 3B (LC3B) homeostasis. In ALS mice (G93A), Atg4b depletion worsens survival rates and autophagy function. For the first time, we observed an elevation of LC3ylation in the CNS of both ALS patients and atg4b−/− mouse spinal cords. Furthermore, LC3ylation modulates the distribution of ATG3 across membrane compartments. Antisense oligonucleotides (ASOs) targeting cryptic exon restore ATG4B mRNA in TARDBP knockdown cells. We further developed multi-target ASOs targeting TDP-43 binding sequences for a broader effect. Importantly, our ASO based in peptide-PMO conjugates show brain distribution post-IV administration, offering a non-invasive ASO-based treatment avenue for neurodegenerative diseases., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. G.M. was supported by grants from Ministerio Ciencia e Innovación (Spain) (PID2021-127534OB-I00). M.P.-O. and R.M.S. were supported by grants from Instituto de Salud Carlos III (PI20/000155, PI23/00176 and PI20/00098). R.P. was supported by Generalitat de Catalunya (2021 SGR 00990). P.T. was supported by an Unzué-Luzón grant. P.T. received a Margarita Salas postdoctoral fellowship from the Spanish Ministry of Universities (Spanish Government) which was supported by NextGenerationEU. Work supported by IRBLleida Scientific and Technical Service of Immunohistochemistry.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Exploring platelet metabolomics and fatty acid profiles for ALS prognosis and diagnosis

  • Torres Cabestany, Pascual
  • Pradas, Irene
  • Fernández Bernal, Anna
  • Povedano, Mònica
  • Dominguez, Raul
  • Jové Font, Mariona
  • González Mingot, Cristina
  • Ayala Jové, Ma. Victoria (Maria Victoria)
  • Ferrer, Isidre
  • Pamplona Gras, Reinald
  • Portero Otín, Manuel
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with heterogeneous clinical progression, reflecting distinct underlying pathological mechanisms. Early and accurate diagnosis and prognosis require reliable biomarkers to improve clinical management and therapeutic stratification. The present study explores the potential of platelet global metabolomics and fatty acid (FA) profiling as potential sources of diagnostic and prognostic biomarkers for ALS. We analysed platelets from 15 recently diagnosed ALS patients and 21 healthy controls (CTLs) using liquid chromatography-mass spectrometry (LC-MS) for metabolomics and gas chromatography-flame ionization detection (GC-FID) for FA profiling. ALS patients were classified as fast or slow progressors based on the median ALS Functional Rating Scale-Revised (ALSFRS-R) slope. While global metabolomic and FA profiles have shown limited potential for distinguishing ALS from CTL, preliminary molecular annotation based on mass and retention times disclosed specific metabolites with potential diagnostic value. Importantly, both global metabolomic and FA analyses demonstrated a marked capacity to differentiate fast progressors from slow progressors (receiver operating characteristic (ROC) curves of approximately 1), revealing distinct metabolic signatures associated with disease progression. Our findings demonstrate that platelet global metabolomics and FA profiling hold promise as prognostic biomarkers in ALS., We acknowledge funding from the Spanish Ministry of Economy and Competitiveness, Institute of Health Carlos III (PI20/0155; PI23/00176) to MP-O; from the Spanish Ministry of Science, Innovation and Universities (RTI2018-099200-B-I00), and the Generalitat of Catalonia (Agency for Management of University and Research Grants (2017SGR696) and Department of Health (SLT002/16/00250)) to RP. Support was also received in the form of a FUNDELA Grant, RedELA-Plataforma Investigación, and the Fundació Miquel Valls (Jack Van den Hoek donation). M.J, is a professor under the Serra Hunter program (Generalitat de Catalunya). This study has been co-financed by FEDER funds from the European Union (“A way to build Europe”) and funded by the PIRS program by the “Diputació de Lleida” and by the “la Caixa” Foundation. IRBLleida is funded by a CERCA Programme/Generalitat of Catalonia. P.T. received a Margarita Salas postdoctoral fellowship from the Spanish Ministry of Universities (Spanish Government), which was supported by NextGenerationEU. P.T. received a Beatriu de Pinós postdoctoral fellowship from the Departament de Recerca i Universitats de la Generalitat de Catalunya (2023 BP 00144).
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

NRF2 deficit prevents pathologic Tau seeding and spreading in an induced tauopathy mouse model

  • López Sampere, Yaiza
  • Mengod Soler, Pol
  • Roca Pereira, Sergio
  • Vinyals, Antonia
  • Mato Blanco, Xoel
  • Vela Martínez, Marta
  • Dakterzada, Farida
  • Romero El Khayat, Leila
  • Santamaría, Enrique
  • Fernández Irigoyen, Joaquín
  • Ferrer, Isidro
  • Povedano, Mónica
  • Del Rio, José Antonio
  • Santpere, Gabriel
  • Portero Otín, Manuel
  • Piñol Ripoll, Gerard
  • Andrés Benito, Pol
Background Nuclear factor erythroid 2–related factor 2 (NRF2) regulates antioxidant defenses and protects against neurodegeneration, including Alzheimer's disease (AD). Its age-related decline disrupts redox balance and increases neuronal vulnerability, but the early hippocampal effects remain unclear. Here, we tested whether NRF2 loss affects tau seeding and spreading in a PHF-tau–inoculated mouse model, contributing to accelerated aging. Methodology Three-month-old NRF2-knockout (Nfe2l2−/−) and wild-type (WT) mice received hippocampal inoculations of human AD-derived PHF-tau, and tau propagation was analyzed after three months. To elucidate the molecular underpinnings of the observed changes, we performed integrative phosphoproteotranscriptomic analyses of hippocampal tissue, supported by RT-qPCR and Western blot validation. Results PHF-tau inoculation at 3 months of age in Nfe2l2−/− mice, surprisingly, exhibited markedly reduced tau seeding and spreading compared to WT after 3 months of incubation. Molecular characterization of the Nfe2l2−/− hippocampus was carried out to unravel the molecular changes associated with impaired tau propagation. Transcriptomic profiling revealed 745 deregulated genes in Nfe2l2−/− mice, characterized by upregulation of immune and metabolic pathways but downregulation of oxidative stress and redox-related genes. RT-qPCR confirmed diminished expression of antioxidant enzymes and anti-inflammatory receptors, alongside altered astrocytic markers. Proteomic analysis identified 157 dysregulated proteins associated with mitochondrial, synaptic, and inflammatory processes, while phosphoproteomics detected 824 altered phosphosites enriched in cytoskeletal and synaptic networks. Western blot showed increased GFAP-C-term, AQP4, 8-OHdG, and MDAL, with reduced GSTM2 expression. Notably, total and 4R-tau levels were decreased, while 3R-tau was elevated in Nfe2l2−/− mice. Conclusion Our findings suggest that NRF2 loss induces a hippocampal state marked by impaired antioxidant defenses, astrocytic remodeling, and disrupted tau isoform balance. This environment, while metabolically altered, paradoxically hinders tau propagation, highlighting NRF2 as a key regulator of both redox and cellular maturity programs essential for tau spread and as a potential therapeutic target in tauopathies., MPO was supported by grants from the Instituto de Salud Carlos III (PI20/000155, PI23/00176), and PAB was supported by grants from the same governmental institution (CD23/00097). The project that gave rise to these results received the support of a fellowship to PMS from Fundaci´on Ram´on Areces. We want to particularly acknowledge patients and Biobank HUB-ICO-IDIBELL (PT20/00171) integrated in the ISCIII Biobanks and Biomodels Platform and Xarxa Banc de Tumors de Cata lunya (XBTC) for their collaboration. We thank CERCA Programme/ Generalitat de Catalunya for institutional support.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

NRF2 deficit prevents pathologic Tau seeding and spreading in an induced tauopathy mouse model

  • López Sampere, Yaiza
  • Mengod Soler, Pol
  • Roca Pereira, Sergio
  • Vinyals, Antonia
  • Mato Blanco, Xoel
  • Vela Martínez, Marta
  • Dakterzada, Farida
  • Romero El Khayat, Leila
  • Santamaría, Enrique
  • Fernández Irigoyen, Joaquín
  • Ferrer, Isidro
  • Povedano, Mónica
  • Del Rio, José Antonio
  • Santpere, Gabriel
  • Portero Otín, Manuel
  • Piñol Ripoll, Gerard
  • Andrés Benito, Pol
Background Nuclear factor erythroid 2–related factor 2 (NRF2) regulates antioxidant defenses and protects against neurodegeneration, including Alzheimer's disease (AD). Its age-related decline disrupts redox balance and increases neuronal vulnerability, but the early hippocampal effects remain unclear. Here, we tested whether NRF2 loss affects tau seeding and spreading in a PHF-tau–inoculated mouse model, contributing to accelerated aging. Methodology Three-month-old NRF2-knockout (Nfe2l2−/−) and wild-type (WT) mice received hippocampal inoculations of human AD-derived PHF-tau, and tau propagation was analyzed after three months. To elucidate the molecular underpinnings of the observed changes, we performed integrative phosphoproteotranscriptomic analyses of hippocampal tissue, supported by RT-qPCR and Western blot validation. Results PHF-tau inoculation at 3 months of age in Nfe2l2−/− mice, surprisingly, exhibited markedly reduced tau seeding and spreading compared to WT after 3 months of incubation. Molecular characterization of the Nfe2l2−/− hippocampus was carried out to unravel the molecular changes associated with impaired tau propagation. Transcriptomic profiling revealed 745 deregulated genes in Nfe2l2−/− mice, characterized by upregulation of immune and metabolic pathways but downregulation of oxidative stress and redox-related genes. RT-qPCR confirmed diminished expression of antioxidant enzymes and anti-inflammatory receptors, alongside altered astrocytic markers. Proteomic analysis identified 157 dysregulated proteins associated with mitochondrial, synaptic, and inflammatory processes, while phosphoproteomics detected 824 altered phosphosites enriched in cytoskeletal and synaptic networks. Western blot showed increased GFAP-C-term, AQP4, 8-OHdG, and MDAL, with reduced GSTM2 expression. Notably, total and 4R-tau levels were decreased, while 3R-tau was elevated in Nfe2l2−/− mice. Conclusion Our findings suggest that NRF2 loss induces a hippocampal state marked by impaired antioxidant defenses, astrocytic remodeling, and disrupted tau isoform balance. This environment, while metabolically altered, paradoxically hinders tau propagation, highlighting NRF2 as a key regulator of both redox and cellular maturity programs essential for tau spread and as a potential therapeutic target in tauopathies., MPO was supported by grants from the Instituto de Salud Carlos III (PI20/000155, PI23/00176), and PAB was supported by grants from the same governmental institution (CD23/00097). The project that gave rise to these results received the support of a fellowship to PMS from Fundaci´on Ram´on Areces. We want to particularly acknowledge patients and Biobank HUB-ICO-IDIBELL (PT20/00171) integrated in the ISCIII Biobanks and Biomodels Platform and Xarxa Banc de Tumors de Cata lunya (XBTC) for their collaboration. We thank CERCA Programme/ Generalitat de Catalunya for institutional support.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Exploring platelet metabolomics and fatty acid profiles for ALS prognosis and diagnosis

  • Torres Cabestany, Pascual
  • Pradas, Irene
  • Fernández Bernal, Anna
  • Povedano, Mònica
  • Dominguez, Raul
  • Jové Font, Mariona
  • González Mingot, Cristina
  • Ayala Jové, Ma. Victoria (Maria Victoria)
  • Ferrer, Isidre
  • Pamplona Gras, Reinald
  • Portero Otín, Manuel
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with heterogeneous clinical progression, reflecting distinct underlying pathological mechanisms. Early and accurate diagnosis and prognosis require reliable biomarkers to improve clinical management and therapeutic stratification. The present study explores the potential of platelet global metabolomics and fatty acid (FA) profiling as potential sources of diagnostic and prognostic biomarkers for ALS. We analysed platelets from 15 recently diagnosed ALS patients and 21 healthy controls (CTLs) using liquid chromatography-mass spectrometry (LC-MS) for metabolomics and gas chromatography-flame ionization detection (GC-FID) for FA profiling. ALS patients were classified as fast or slow progressors based on the median ALS Functional Rating Scale-Revised (ALSFRS-R) slope. While global metabolomic and FA profiles have shown limited potential for distinguishing ALS from CTL, preliminary molecular annotation based on mass and retention times disclosed specific metabolites with potential diagnostic value. Importantly, both global metabolomic and FA analyses demonstrated a marked capacity to differentiate fast progressors from slow progressors (receiver operating characteristic (ROC) curves of approximately 1), revealing distinct metabolic signatures associated with disease progression. Our findings demonstrate that platelet global metabolomics and FA profiling hold promise as prognostic biomarkers in ALS., We acknowledge funding from the Spanish Ministry of Economy and Competitiveness, Institute of Health Carlos III (PI20/0155; PI23/00176) to MP-O; from the Spanish Ministry of Science, Innovation and Universities (RTI2018-099200-B-I00), and the Generalitat of Catalonia (Agency for Management of University and Research Grants (2017SGR696) and Department of Health (SLT002/16/00250)) to RP. Support was also received in the form of a FUNDELA Grant, RedELA-Plataforma Investigación, and the Fundació Miquel Valls (Jack Van den Hoek donation). M.J, is a professor under the Serra Hunter program (Generalitat de Catalunya). This study has been co-financed by FEDER funds from the European Union (“A way to build Europe”) and funded by the PIRS program by the “Diputació de Lleida” and by the “la Caixa” Foundation. IRBLleida is funded by a CERCA Programme/Generalitat of Catalonia. P.T. received a Margarita Salas postdoctoral fellowship from the Spanish Ministry of Universities (Spanish Government), which was supported by NextGenerationEU. P.T. received a Beatriu de Pinós postdoctoral fellowship from the Departament de Recerca i Universitats de la Generalitat de Catalunya (2023 BP 00144).